Clinical trial navigation can create a clearer path to appropriate care by helping connect treating oncologists with investigators, supporting eligibility review, and guiding patients through the steps needed to evaluate a trial. The goal is to make sure clinically relevant options are visible to the care team early enough to be considered not to steer patients toward trials as a default.
When a trial is clinically appropriate and the study sponsor covers certain study-related costs, that may affect how treatment-related expenses are distributed across the plan, though this should be understood as a potential byproduct of appropriate care, not the primary reason to pursue trial access.
Why Cancer Care Is a Growing Employer Concern
1104Health’s employer and payer approach focuses on this earlier point in the journey. Its model combines an oncology network with tools intended to identify high-risk patients, support treatment planning, and navigate patients toward appropriate options. The company describes clinical trials as one potential care option within that broader process. This reflects a practical principle: cost management should not be separated from clinically appropriate care coordination.
Where Cancer Costs Can Become Difficult to Manage
Cancer spending can become harder to manage when information is incomplete or when care moves between disconnected settings. A patient may receive care from a community oncologist while a relevant specialist or clinical trial is available elsewhere. Without a reliable way to connect those professionals, an opportunity can be missed.
Two areas deserve particular attention:
- Earlier identification: Claims and clinical information may help employers and their partners recognize members whose cancer care may require closer review, subject to privacy, clinical, and regulatory requirements.
- Treatment and trial awareness: Appropriate biomarker testing, treatment review, second opinions, and clinical trial awareness can help make available options easier to consider at relevant points in care.
This does not mean every patient should pursue a clinical trial or that every trial will be less expensive. Clinical appropriateness remains central. The objective is to make potentially relevant options visible early enough for the treating team and patient to evaluate them.
How Clinical Trial Navigation Can Support Cancer Care Cost Management
Clinical trial navigation can connect several steps that are often separated in traditional care. It begins with identifying a patient who may meet the clinical requirements of a study. The next step is confirming eligibility, communicating with the treating oncology team, connecting with an investigator or trial site, and helping the patient understand the practical process.
This matters because a trial match alone does not create access. The company notes that patients may miss trials because referrals happen too late, records do not move quickly, or treating physicians and investigators lack an established connection. Its Shared Care approach is designed to support communication and coordination across those settings.
Why Timing Matters
Cancer treatment decisions can change quickly. Eligibility criteria can be specific, and some studies require patients to meet defined clinical or treatment-history requirements. If trial awareness begins only after several lines of therapy, a patient may no longer qualify for an option that could have been considered earlier.
This is why proactive identification can matter within an oncology benefits strategy. Employers and their clinical partners can consider whether high-risk members are being identified early enough for appropriate clinical review, whether biomarker information is available when needed, and whether physicians have practical pathways for discussing relevant trials.
The Role of Biomarker Testing
Biomarker testing can influence how clinicians understand a patient’s cancer and which treatment options may be relevant. In some cancers, biomarker results can help identify targeted therapies or clinical trials designed around specific molecular or biological characteristics.
For employers, the cost-management question is therefore connected to the quality and timing of diagnostic information. If clinically appropriate testing is not considered, a potentially relevant treatment pathway may be harder to identify. At the same time, broader testing is not automatically better for every patient. Testing decisions should be based on the cancer type, clinical circumstances, evidence, and the treating physician’s judgment.
A thoughtful cancer care cost management approach should therefore look beyond claims totals. It should consider whether the care pathway provides clinicians with the information they need to evaluate appropriate treatment options.
Shared Care Keeps Clinical Trial Access Connected to the Patient
Clinical trial navigation is more useful when it does not require a patient to leave the physician they already trust. A shared care model allows local oncologists, specialists, investigators, navigators, and other members of the care team to remain connected as treatment decisions develop.
Its Shared Care Network is a physician-first infrastructure that supports collaboration, patient identification and trial matching, education, and navigation. The platform is designed to fit within existing oncology practices rather than replace them.
What Employers Should Look for in Clinical Trial Navigation
A strong program should be evaluated on more than the number of trials in a database. Employers should ask how the service connects clinical information, physicians, investigators, patients, and benefits stakeholders.
Consider these areas:
- Clinical relevance: Is trial eligibility reviewed in the context of the patient’s diagnosis, treatment history, and clinical needs?
- Physician collaboration: Can the treating oncologist participate in the process and remain informed?
- Navigation support: Does someone help coordinate records, referrals, communication, and practical next steps?
- Cost transparency: Can the employer distinguish potential sponsor-covered study costs from routine care and plan-covered services?
- Measurement: Are outcomes, utilization, and financial results evaluated carefully rather than assumed?
- Patient experience: Is the process designed to preserve choice, informed decision-making, and continuity of care?
EXPLORE 1104HEALTH’S ONCOLOGY APPROACH
The Role of Stop-Loss Carriers
Stop-loss carriers have a particular interest in high-cost cancer claims because severe episodes can materially affect plan risk. A stop-loss carrier’s role in managing high-cost claims is not to determine treatment. Rather, the focus can include identifying opportunities for appropriate clinical review, care coordination, and earlier intervention within the terms of the plan and policy.
Employers should also review applicable federal requirements, including clinical trial coverage rules and any CAA-2021 provisions relevant to their plan, with qualified legal and benefits advisors rather than relying on this article as an interpretation.
This is important when clinical trial coverage, reporting, or participant protections are involved.
Building a More Connected Cancer Strategy
Reducing cancer spending responsibly requires more than looking for the lowest-priced service. It requires understanding where care becomes fragmented and where earlier clinical coordination may help patients and employers.
Clinical trial navigation can contribute by making relevant studies easier to identify, supporting communication between community oncologists and investigators, and helping patients move through referral and evaluation steps. When appropriate, trial participation may also change the distribution of certain treatment-related costs.
1104Health places these functions within a Shared Care model that connects oncologists, investigators, navigators, and patients. Its employer-facing approach also includes claims analysis and a focus on high-risk patient identification. These elements reflect a broader view of cancer care cost management: understand the population, identify appropriate opportunities, coordinate with clinicians, and evaluate the results carefully.
For employers, the opportunity is not to promise that every cancer episode can be made less expensive. It is to build a more informed pathway in which appropriate treatment options are considered at a clinically relevant time, patients receive support through complex decisions, and financial implications are understood alongside clinical needs.
Frequently Asked Questions
1. Why is cancer care a major driver of employer healthcare costs?
Cancer can generate substantial spending because treatment may involve multiple specialties, advanced therapies, hospital services, diagnostics, and prolonged care. The financial impact varies by cancer type, stage, treatment, and individual circumstances. This makes cancer care cost management a matter of informed, case-by-case coordination. Employers can focus on earlier identification, appropriate care coordination, and informed treatment pathways rather than assuming that one intervention will address every high-cost case.
2. Can clinical trials lower employer healthcare spend?
Clinical trials do not automatically lower costs. When an employee is clinically eligible for an appropriate trial, the study sponsor may cover certain investigational treatment or study-related expenses. That can change which costs are paid by the health plan. Routine care and other services may still remain the plan’s responsibility, so each trial requires careful review of coverage and financial terms.
3. How can employers identify high-risk cancer patients early?
Employers and their clinical partners may use claims and other permitted healthcare data to identify patterns associated with complex or high-cost cancer care. The next step should be appropriate clinical review, not automatic treatment direction. Early identification can create an opportunity to evaluate care coordination, specialist input, biomarker testing, second opinions, or trial eligibility when clinically appropriate.
4. How does biomarker testing affect cancer treatment costs?
Biomarker testing can provide information that helps clinicians evaluate targeted therapies and certain clinical trials. Its value depends on the cancer type, the test used, and the patient’s clinical circumstances. Testing can influence treatment selection, but it should be ordered and interpreted according to clinical judgment and applicable guidelines. Employers should focus on supporting appropriate access rather than promoting testing without a clinical reason.
5. What is a Shared Care model in oncology benefits?
A Shared Care model connects physicians and other care participants across settings so that specialized cancer care can be coordinated without unnecessarily separating patients from their existing oncologists. In an oncology benefits context, it can support trial awareness, referrals, navigation, and communication while keeping clinical decisions with the patient and treating physicians. 1104Health uses this model as the foundation of its oncology collaboration network.
Conclusion
Clinical trial navigation can be a meaningful component of an employer’s cancer strategy when it is built around clinical appropriateness, timely identification, physician collaboration, patient support, and transparent cost considerations. It should not be treated as a promise of savings or as a replacement for sound oncology care.
For self-funded employers and their benefits partners, the more useful question is whether employees have a clear path to appropriate options before opportunities are missed. A connected approach can bring clinical trial awareness, biomarker information, specialist collaboration, and patient navigation into the same care journey. That creates a more thoughtful foundation for managing cancer costs while keeping the quality, continuity, and dignity of patient care at the center.
